Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

ConclusionERD-148 inhibits the growth of ER-positive breast cancer cells via downregulating ER α with comparable potency to Fulvestrant with marginal non-specific toxicity.

http://link.springer.com/10.1007/s10549-020-05564-y

Source: Breast Cancer Research and Treatment - February 16, 2020 Category: Cancer & Oncology Source Type: research